[go: up one dir, main page]

WO1997011667A3 - Utilisation therapeutique de serums d'animaux, en particulier du cheval, pour le traitement du sida, du cancer et d'autres maladies virales et bacteriennes - Google Patents

Utilisation therapeutique de serums d'animaux, en particulier du cheval, pour le traitement du sida, du cancer et d'autres maladies virales et bacteriennes Download PDF

Info

Publication number
WO1997011667A3
WO1997011667A3 PCT/IB1996/001115 IB9601115W WO9711667A3 WO 1997011667 A3 WO1997011667 A3 WO 1997011667A3 IB 9601115 W IB9601115 W IB 9601115W WO 9711667 A3 WO9711667 A3 WO 9711667A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic applications
horse serum
sera
viral
aids
Prior art date
Application number
PCT/IB1996/001115
Other languages
English (en)
Other versions
WO1997011667A2 (fr
Inventor
Samir Chachoua
Original Assignee
Samir Chachoua
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samir Chachoua filed Critical Samir Chachoua
Priority to AU71431/96A priority Critical patent/AU7143196A/en
Priority to EP96932773A priority patent/EP0853486A4/fr
Publication of WO1997011667A2 publication Critical patent/WO1997011667A2/fr
Publication of WO1997011667A3 publication Critical patent/WO1997011667A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne de nouvelles utilisations de sérums d'animaux, en particulier du cheval, pour le traitement, le diagnostic et la gestion clinique du SIDA, de cancers et d'autres maladies virales et bactériennes.
PCT/IB1996/001115 1995-09-25 1996-09-25 Utilisation therapeutique de serums d'animaux, en particulier du cheval, pour le traitement du sida, du cancer et d'autres maladies virales et bacteriennes WO1997011667A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU71431/96A AU7143196A (en) 1995-09-25 1996-09-25 Therapeutic applications of animal sera including horse serum in the treatment of aids, cancer, and other viral and bacterial diseases
EP96932773A EP0853486A4 (fr) 1995-09-25 1996-09-25 Utilisation therapeutique de serums d'animaux, en particulier du cheval, pour le traitement du sida, du cancer et d'autres maladies virales et bacteriennes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US428195P 1995-09-25 1995-09-25
US60/004,281 1995-09-25

Publications (2)

Publication Number Publication Date
WO1997011667A2 WO1997011667A2 (fr) 1997-04-03
WO1997011667A3 true WO1997011667A3 (fr) 1997-06-12

Family

ID=21710013

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB1996/001059 WO1997011666A2 (fr) 1995-09-25 1996-09-25 Utilisation de 2-mercaptoethanolamine (2-mea) et de composes aminothiols similaires, en combinaison avec du 3,5-diisopropyl-salicylate de cuivre (ii) et des composes similaires, pour le traitement et la prevention de differentes maladies
PCT/IB1996/001115 WO1997011667A2 (fr) 1995-09-25 1996-09-25 Utilisation therapeutique de serums d'animaux, en particulier du cheval, pour le traitement du sida, du cancer et d'autres maladies virales et bacteriennes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/IB1996/001059 WO1997011666A2 (fr) 1995-09-25 1996-09-25 Utilisation de 2-mercaptoethanolamine (2-mea) et de composes aminothiols similaires, en combinaison avec du 3,5-diisopropyl-salicylate de cuivre (ii) et des composes similaires, pour le traitement et la prevention de differentes maladies

Country Status (5)

Country Link
EP (2) EP0858327A2 (fr)
JP (1) JPH11514990A (fr)
AU (2) AU6999096A (fr)
CA (2) CA2233015A1 (fr)
WO (2) WO1997011666A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994409A (en) 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6384259B1 (en) 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
AU776732B2 (en) * 1999-10-04 2004-09-23 John Carter Pharmaceutical compositions containing copper, salicylic acid and vitamines C
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US7927612B2 (en) 2000-01-19 2011-04-19 Baofa Yu Combinations and methods for treating neoplasms
US6506413B1 (en) * 2001-04-30 2003-01-14 Joseph C. Ramaekers Compositions for treating animal diseases and syndromes
US7053072B2 (en) 2001-05-11 2006-05-30 Medimmune Oncology, Inc. Methods for the administration of amifostine and related compounds
FR2825923B1 (fr) * 2001-06-15 2006-04-07 Oreal Inhibiteur de no-synthase et utilisations
KR20030077743A (ko) * 2002-03-26 2003-10-04 변현규 In½
US7629333B2 (en) 2002-03-29 2009-12-08 Medimmune, Llc Stable amorphous amifostine compositions and methods for the preparation and use of same
AU2002353346A1 (en) * 2002-09-10 2004-04-30 Samir Chachoua Induced remission therapy
GB2398497A (en) * 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
US9125874B2 (en) 2007-11-30 2015-09-08 The Ramaekers Family Trust Administration of transfer factor for improving reproductive health
CN101138634A (zh) 2006-09-07 2008-03-12 于保法 用于治疗肿瘤的组合物
WO2009070788A1 (fr) 2007-11-30 2009-06-04 The Ramaekers Family Trust Compositions et procédés d'amélioration de la fertilité
WO2010093606A1 (fr) * 2009-02-11 2010-08-19 Martin Heath Bluth Echange réciproque sérum/plasma pour le traitement du cancer
AU2015353539A1 (en) 2014-11-26 2017-07-13 Baofa Yu Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228127A (en) * 1978-10-06 1980-10-14 International Radioimmune Systems, Inc. Kit for detecting human chorionic gonadotropin
US5310653A (en) * 1989-10-24 1994-05-10 Board Of Regents, The University Of Texas System Tumor marker protein and antibodies thereto for cancer risk assessment or diagnosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952607A (en) * 1982-05-27 1990-08-28 International Copper Research Association, Inc. Copper complex for treating cancer
US5057314A (en) * 1988-09-30 1991-10-15 Whitfill Craig E Low molecular weight antiviral factors
US5488042A (en) * 1992-03-13 1996-01-30 Arch Development Corporation Method for protection against genotoxic mutagenesis
DE4236069A1 (de) * 1992-10-26 1994-04-28 Werner Dr Bergmann Arzneimittel, insbesondere für orale Einnahme
AU7098694A (en) * 1993-06-07 1995-01-03 Center For Special Immunology Adoptive immune reconstitution treatment for patients with acquired immunodeficiencies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228127A (en) * 1978-10-06 1980-10-14 International Radioimmune Systems, Inc. Kit for detecting human chorionic gonadotropin
US5310653A (en) * 1989-10-24 1994-05-10 Board Of Regents, The University Of Texas System Tumor marker protein and antibodies thereto for cancer risk assessment or diagnosis

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
ACTA HAEMAT., 1985, Vol. 74, No. 1, MARMONT et al., "Positive Direct Antiglobulin Tests and Heteroimmune Hemolysis in Patients With Severe Aplastic Anemia and Pure Red Cell Anemia Treated With Atilymphocytic Globulin", pages 14-18. *
AM. J. PHYSIOL., 1993, Vol. 265, No. 2, Part 2, SMITH et al., "Experimental Cachexia: Effects of MCA Sarcoma in the Fisher Rat", pages R376-R384. *
ARCH. GESCHWULSTFORSCH., 1976, Vol. 46, No. 4, LAZAREV et al., "Inhibition of Subcutaneous Ehrlich Carcinoma by Antihuman-Somatotropic Hormone Serum of the Horse as Determined by the Tumour-Tetanus Assay of the Mouse", pages 261-270. *
ARCHIVUM IMMUNOLOGIAE ET THERAPIE EXPERIMENTALIS, 1977, Vol. 25, No. 3, BRATKOWSKA-SENIOW et al., "Obtaining, Evaluation and Clinical Application of Antileukemic Antilymphocyte Globulin (ALLG) in the Treatment of Chronic Lymphatic Leukemia", pages 349-365. *
CANCER RESEARCH, 15 April 1988, Vol. 48, No. 8, CHODAK et al., "Increased Levels of Fibroblast Growth Factor-Like Activity in Urine from Patients With Bladder or Kidney Cancer", pages 2083-2088. *
CHEM.-BIOL. INTERACTIONS, June 1976, Vol. 13, No. 3/4, GIRALDI et al., "Antitumour Activity of Equinatoxin", pages 199-203. *
EUROP. J. CANCER, 1976, Vol. 12, No. 1, SCHERER et al., "The Effect of Antilymphocytic and Normal Horse Serum on Growth of Precancerous Foci and Development of Tumours Induced by Diethylnitrosamine in Rat Liver", pages 25-31. *
INT. J. CANCER, 15 May 1980, Vol. 25, No. 5, WEPSIC et al., "Effect of Horse Antibody to Rat Alpha-Fetoprotein Upon the Growth of AH-66 in Donryu Rats", pages 655-661. *
INT. J. CANCER, 1984, Vol. 33, No. 4, OHKAWA et al., "The Inhibitory Effects of Horse Anti-Rat AFP Antiserum on the Uptake of 2-Deoxy-D-Glucose by AFP-Producing Rat Hepatoma Cells", pages 497-502. *
INT. J. CANCER, January 1974, Vol. 13, No. 2, TSUKADA et al., "Effect on Anti-Alpha-Fetoprotein Serum on Some Cultured Tumor Cells", pages 187-195. *
J. ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1990, Vol. 3, No. 1, PEREZ et al., "HIV-1 and HTLV-1 Infection in Renal Transplant Recipients", pages 35-40. *
J. CHROMATOGR., 1981, Vol. 215, HIRAI et al., "Purification of Specific Antibody to alpha-Foetoprotein and its Immunological Effect on Cancer Cells", pages 195-210. *
J. PAEDIATR. CHILD HEALTH, 1992, Vol. 28, No. 4, GIRI et al., "Failure of Allogenic Bone Marrow Transplantation to Benefit HIV Infection", pages 331-333. *
JAMA, 03 March 1993, Vol. 269, No. 9, JEWETT et al., "Preventive Health Care for Adults With HIV Infection", pages 1144-1153. *
LYMPHOKINE RESEARCH, 1985, Vol. 4, No. 3, NKRUMAH et al., "Regression of Progressive Lymphadenopathy in a Young Child With Acute Cytomegalovirus (CMV) Infection Following the Administration of Transfer Factor With Specific Anti-CMV Activity", pages 237-241. *
NEOPLASMA, 1974, Vol. 21, No. 3, MIHAESCU et al., "Treatment of Ascites Tumour With Cytolytic Serum Obtained by Double Immunization", pages 297-195. *
PROC. NATL. ACAD. SCI. U.S.A., June 1992, Vol. 89, No. 12, NAKANISHI et al., "Direct Effect of Basic Fibroblast Growth Factor on Gene Transcription in a Cell-free System", pages 5216-5220. *
PROGRAM ABSTR. INTERSCI. CONF. ANTIMICROB. AGENTS CHEMOTHER., October 1994, GUNNARSSON et al., "Effect of Combinations of Cysteamine (Mercaptoethylamine, MEA) and Nucleoside Reverse Transcriptase (RT) Inhibitors on HIV-1 Replication in Vitro", page 93, Abstract 192. *
See also references of EP0853486A4 *

Also Published As

Publication number Publication date
WO1997011666A2 (fr) 1997-04-03
WO1997011666A3 (fr) 1997-06-19
EP0858327A2 (fr) 1998-08-19
EP0853486A4 (fr) 2001-09-26
AU6999096A (en) 1997-04-17
EP0853486A2 (fr) 1998-07-22
CA2233015A1 (fr) 1997-04-03
CA2233445A1 (fr) 1997-04-03
JPH11514990A (ja) 1999-12-21
AU7143196A (en) 1997-04-17
WO1997011667A2 (fr) 1997-04-03

Similar Documents

Publication Publication Date Title
WO1997011667A3 (fr) Utilisation therapeutique de serums d&#39;animaux, en particulier du cheval, pour le traitement du sida, du cancer et d&#39;autres maladies virales et bacteriennes
EP0853486A3 (fr) Utilisation therapeutique de serums d&#39;animaux, en particulier du cheval, pour le traitement du sida, du cancer et d&#39;autres maladies virales et bacteriennes
AU2993297A (en) Treatment of sickle cell disease, treatment of immune system diseases and other diseases normally associated with sickle cell anemia
EP1293565A3 (fr) Composante ARN de la télomérase de mammifères
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
CA2284876A1 (fr) Microphone implantable
WO1994011026A3 (fr) Application therapeutique d&#39;anticorps chimeriques et radio-marques contre l&#39;antigene a differentiation restreinte des lymphocytes b humains pour le traitement du lymphome des cellules b
FI963101L (fi) Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoon, joissa seerumin interleukiini-6-taso on kohonnut
EP0671920A4 (fr) Anticorps anti-idiotypique et utilisation diagnostique et therapeutique pour les affections dues au vih.
CA2212058A1 (fr) Preparation et utilisation d&#39;un ligand specifique du recepteur gaba-a.alpha.5 destine au traitement de la maladie d&#39;alzheimer
AU2990695A (en) Mucin-derived proteins for the diagnosis, imaging, and therapy of human cancer
WO1996001614A3 (fr) Composant d&#39;arn de la telomerase
WO1998019167A3 (fr) Gene de classe i du complexe majeur d&#39;histocompatibilite humain a stress cellulaire regule
AU9312198A (en) Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer
EP1053315A4 (fr) Gene de la calvitie chez l&#39;homme, proteine et utilisations associees
AU2001285210A1 (en) Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
WO1997018790A3 (fr) Agents therapeutiques et de diagnostic pour traiter les infections microbiennes
AU9363398A (en) Hepatitis c receptor protein cd81
EP0795332A3 (fr) Utilisation médicale de gamma interféron dans les maladies pulmonaires interstitielles
CA2271478A1 (fr) Expression specifique tissulaire de la proteine du retinoblastome
FR2757864B1 (fr) Anticorps reconnaissant specifiquement une proteine nitrosylee, leur procede de preparation, leur utilisation therapeutique et diagnostique
AU1820499A (en) Compounds and methods for the diagnosis and treatment of (b. microti) infection
DE59611307D1 (de) Nucleinsäure-moleküle codierend proteine, die die adhäsion von neisseria-zellen an humane zellen vermitteln
HK1015268A (en) Therapeutic applications of animal sera including horse serum in the treatment of aids, cancer, and other viral and bacterial diseases
AU7974791A (en) Identification of novel drugs and reagents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU BB BG BR CA CN CU CZ EE FI GE HU IS JP KE KG KP KR LK LR LT LV MD MG MK MN MW MX NO NZ PL RO SG SI SK TR TT UA UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU BB BG BR CA CN CU CZ EE FI GE HU IS JP KE KG KP KR LK LR LT LV MD MG MK MN MW MX NO NZ PL RO SG SI SK TR TT UA UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2233015

Country of ref document: CA

Ref country code: CA

Ref document number: 2233015

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996932773

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1996932773

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996932773

Country of ref document: EP